Search
sutimlimab-jome (Enjaymo)
Indications:
- treatment of adults with cold agglutinin disease
Dosage:
- weight-based dosage weekly for two weeks then every two weeks
- 39-75 kg: 6500 mg IV infusion
- > 75 mg: 7500 mg IV infusion
- vaccinate against encapsulated bacteria at least two weeks prior to treatment
Injection: 1,100 mg/22 mL (50 mg/mL) in a single-dose vial
Adverse effects:
- > 10%
- respiratory tract infection, viral infection, diarrhea, dyspepsia, cough, arthralgia, arthritis, peripheral edema
Mechanism of action:
- classical complement inhibitor decreases need RBC transfusion due to hemolysis in adults with cold agglutinin disease
Interactions
drug adverse effects of pharmaceutical monoclonal antibodies
General
pharmaceutical monoclonal antibody
hematologic agent
References
- Highlights of Prescribing Information
sutimlimab-jome (Enjaymo)
https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761164s000lbl.pdf